Targeting NTCP for liver disease treatment:A promising strategy
10.1016/j.jpha.2024.100979
- Author:
Tan XIN
1
,
2
;
Xiang YU
;
Shi JIANYOU
;
Chen LU
;
Yu DONGKE
Author Information
1. Department of Pharmacy,Sichuan Provincial People's Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu,610072,China
2. Personalized Drug Therapy Key Laboratory of Sichuan Province,School of Medicine,University of Electronic Science and Technology of China,Chengdu,610072,China
- Keywords:
NTCP;
Bile acids metabolism;
NTCP inhibitor;
Viral hepatitis
- From:
Journal of Pharmaceutical Analysis
2024;14(9):1267-1281
- CountryChina
- Language:Chinese
-
Abstract:
The sodium taurocholate co-transporting polypeptide(NTCP),a bile acids transporter,has been identi-fied as a new therapeutic target for the treatment of liver disease.This paper thoroughly investigates the function of NTCP for regulating bile acid regulation,its correlation with hepatitis B and D infections,and its association with various liver diseases.Additionally,in this review we examine recent breakthroughs in creating NTCP inhibitors and their prospective applications in liver disease treatment.While this review emphasizes the promising potential of targeting NTCP,it concurrently underscores the need for broader and more detailed research to fully understand the long-term implications and potential side effects associated with NTCP inhibition.
